Substance Use Disorders: A Comprehensive Review and Update 2023
We invite you to join us at Disney's Grand Floridian Resort & Spa for our annual Substance Use Disorder conference.
Please click on the "Venue" tab to see our available room block offerings.
Attend this conference on substance use disorders to hear the latest research and find guidance that enhances your care for patients.
Substance use disorders are complex and have a huge impact on patients, families and communities They challenge even experienced health care professionals to stay current with evolving guidelines. And they are seen and treated across all professions, disciplines and practice settings. This includes primary care, psychiatry, social work, psychology, family practice, nursing and more.
That's why our agenda focuses on a broad update across the spectrum of substance use disorders. Sessions cover everything from neuroscience and developmental perspectives all the way through recovery-oriented systems of care. Our faculty share their experience as both clinical caregivers and research experts. They make time to answer questions and help you find solutions for complex conditions.
Pricing
MDs/Doctoral-Level Professionals
Regular Registration (after January 13, 2023): $995.00
Other Professionals or Trainees
Regular Registration (after January 13, 2023): $895.00
Sunday, February 19, 2023
Buprenorphine Waiver Training: $50
This is a ticketed event, NO CME CREDIT
*New* Virtual Registration
We are now adding a full virtual option to accommodate those who can not attend in person. Full more information and to register, please click the link below.
Substance Use Disorders 2023: Virtual Registration - Click Here
E-SYLLABUS
We provide all attendees with completely free access to all slide presentations in digital PDF format prior to the conference. This is an environmentally friendly alternative and helps keep costs lower for all attendees. The e-syllabus will be available for 30 days after the conference.
Cancellation Policy
A refund minus a $100.00 administrative fee will be issued for refund requests received by January 18, 2023. Payments made may not be applied to future conferences or other educational activities. There are no exceptions to these policies.
Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PCSS website link: www.pcssNOW.org
Contact information: pcss@aaap.org
AAAP is the DATA 2000 sponsor for this training.
Massachusetts General Hospital Psychiatry Update & Board Preparation, 4th Edition
Board certification and recertification exams are critical career moments. That is why you should rely on the Massachusetts General Hospital Psychiatry Update & Board Preparation, Fourth Edition. It puts our 80+ years of clinical experience at your fingertips to help you prepare for your exam.
Purchase a print copy of our Board Preparation book here!
Target Audience
This program is intended for:
- General and Family Physicians
- Psychiatrists
- Nurse Practitioners
- Physician Assistants
- Nurses
- Psychologists
- Social Workers
Learning Objectives
Our conference lets you engage dozens of renowned clinician-researchers, get your clinical questions answered, and translate enhanced knowledge into optimal patient care.
Here are some of the ways that participants plan to change their clinical practice as a result of attending our conference:
- Describe the best practices for treatment of substance use disorders
- Discuss how to properly screen and diagnose substance use disorders
- List rational, evidence based pharmacologic and non-pharmacologic therapies for patients with substance use disorders
- Assess relative utility and strengths of recovery oriented models of care
- Assess and treat patients with co-morbid substance use, mood disorders, anxiety disorders, ADHD, pain, and infectious diseases.
- Discuss how to manage complicated withdrawal
- Utilize motivational interviewing, CBT and contingency management techniques when working with patients suffering from substance use disorders
- Describe the effects of and interventions for marijuana and synthetics
- List the different approaches and challenges associated with opioid, alcohol and nicotine treatment
- Discuss the challenges associated with identification and management of substance use disorders in the emergency department
Important: Buprenorphine (MAT) Waiver Training Registrants
You will need to create an account in the PCSS system ahead of the live training. If you do not set up an account and enroll in your training ahead of time, it will delay your ability to complete the online half and receive their certificate of completion. Please use this link to create an account https://education.sudtraining.org/Public/Registration.aspx Once you have created an account in the PCSS system, please use this link to enroll in the online half of this course: https://education.sudtraining.org/Users/InvitationCode.aspx You will submit this code: WAIVER-250359-11951
Once you have entered the invitation code, click “Get Started”, you will have access to the online half of the training. You may complete the online half before or after our live training. After the live training our staff will indicate your attendance. Once both halves of the training are complete you may return to the PCSS platform, complete their evaluation and claim your waiver training certificate.
Effective December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act):
- All DEA registrants should be aware of the following:
- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- The Act does not impact existing state laws or regulations that may be applicable.
While no longer required, the Act also introduced new training requirements for all prescribers who are not board certified in addiction medicine. These requirements will go into effect June 21, 2023, and the DEA and SAMHSA are actively working to provider further guidance.
As such, the MGH Psychiatry Academy welcomes all providers who plan to treat patients with opioid use disorder to make use of existent waiver trainings and other educational resources. Please continue to check https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement for further updates and guidance.
Substance Use Disorders: A Comprehensive Review and Update
February 19-22, 2023
Lake Buena Vista, FL
SUNDAY, FEBRUARY 19, 2023
2:00 – 6:00 PM Buprenorphine (MAT) Waiver Training
Laura G. Kehoe, MD, MPH, FASAM
THIS IS A TICKETED EVENT, NO CME CREDIT
Important: Buprenorphine (MAT) Waiver Training Registrants
You will need to create an account in the PCSS system ahead of the live training. If you do not set up an account and enroll in your training ahead of time, it will delay your ability to complete the online half and receive their certificate of completion. Please use this link to create an account https://education.sudtraining.org/Public/Registration.aspx Once you have created an account in the PCSS system, please use this link to enroll in the online half of this course: https://education.sudtraining.org/Users/InvitationCode.aspx You will submit this code: WAIVER-250359-11951
Once you have entered the invitation code, click “Get Started”, you will have access to the online half of the training. You may complete the online half before or after our live training. After the live training our staff will indicate your attendance. Once both halves of the training are complete you may return to the PCSS platform, complete their evaluation and claim your waiver training certificate.
Effective December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act):
- All DEA registrants should be aware of the following:
- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- The Act does not impact existing state laws or regulations that may be applicable.
While no longer required, the Act also introduced new training requirements for all prescribers who are not board certified in addiction medicine. These requirements will go into effect June 21, 2023, and the DEA and SAMHSA are actively working to provider further guidance.
As such, the MGH Psychiatry Academy welcomes all providers who plan to treat patients with opioid use disorder to make use of existent waiver trainings and other educational resources. Please continue to check https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement for further updates and guidance.
MONDAY, FEBRUARY 20, 2023
8:00 – 8:10 AM Welcome & Introduction
David H. Rubin, MD
MODULE TOPIC 1: TREATMENT IN CONTINUING CARE
8:10 – 8:30 AM Motivational Interviewing
John F. Kelly, PhD
8:30 – 8:50 AM CBT
John F. Kelly, PhD
8:50 – 9:10 AM Helping Family Members
John F. Kelly, PhD
9:10 – 9:30 AM Screening Assessment & Patient Monitoring
Eugene Lambert, MD
9:30 – 10:10 AM Panel Discussion
Moderator: David Rubin, MD
Panelists: John F. Kelly, PhD, Eugene Lambert, MD
10:10 – 10:30 AM Coffee Break
MODULE TOPIC 2: GENERAL PRINCIPLES & CARE DELIVERY
10:30 – 10:50 AM Treating Addiction as a Chronic Disease
Jessica Gray, MD
10:50 – 11:10 AM Harm Reduction
Justin Alves, RN, MSN, ACRN, CARN, CNE
11:10 – 11:30 AM Treating Addiction in Relation to Regulatory Agencies
Laura G. Kehoe, MD, MPH, FASAM
11:30 – 12:10 PM Panel Discussion
Moderator: John Kelly, PhD
Panelists: Jessica Gray, MD, Justin Alves, RN, MSN, ACRN, CARN, CNE
12:10 – 1:10 PM Lunch Break
MODULE TOPIC 3: RECOVERY SUPPORT SERVICES
1:10 – 1:30 PM Self-Help Treatments
John F. Kelly, PhD
1:30 – 1:50 PM Recovery Coaching & Residences
Justin Alves, RN, MSN, ACRN, CARN, CNE
1:50 – 2:10 PM Panel Discussion
Moderator: John Kelly, PhD
Panelists: Justin Alves, RN, MSN, ACRN, CARN, CNE
2:10 – 2:30 PM Coffee Break
MODULE TOPIC 4: OPIOID
2:30 – 2:50 PM Buprenorphine 101
Laura G. Kehoe, MD, MPH, FASAM
2:50 – 3:10 PM Buprenorphine: low dose inductions and extended release
Eugene Lambert, MD
3:10 – 3:30 PM Naltrexone Intramuscular & Methadone
Laura G. Kehoe, MD, MPH, FASAM
3:30 – 3:50 PM Pregnancy
Jessica Gray, MD
3:50 – 4:30 PM Panel Discussion
Moderator: Laura G. Kehoe, MD, MPH, FASAM
Panelists: Jessica Gray, MD, Eugene Lambert, MD
4:30 PM Adjourn
TUESDAY, FEBRUARY 21, 2023
8:00 – 8:10 AM Welcome & Introduction
Timothy E. Wilens, MD
MODULE TOPIC 5: NEUROSCIENCE
8:10– 8:30 AM Neurobiology of Addiction
Timothy E. Wilens, MD
8:30 - 8:50 AM Genetics of Substance Use Disorders
Robert R. Althoff, MD, PhD
8:50 – 9:10 AM Evolutionary Theories of Substance Use
David H. Rubin, MD
9:10 – 9:30 PM Coffee Break
MODULE TOPIC 6: ALCOHOL, SEDATIVES & HYPNOTICS
9:30 - 9:50 AM Alcohol
Vinod Rao, MD, PhD
9:50 – 10:10 AM Alcohol Part II
Vinod Rao, MD, PhD
10:10 – 10:30 AM Sedatives & Hypnotics
Robert R. Althoff, MD, PhD
10:30 – 10:50 AM Benzodiazepines & Addiction
Timothy Wilens, MD
10:50 – 11:10 AM Alcohol & Hepatitis
Eugene Lambert, MD
11:10 – 11:50 AM Panel Discussion
Moderator: Jessica Gray, MD,
Panelists: Vinod Rao, MD, PhD, Robert R. Althoff, MD, PhD, Timothy Wilens, MD, Eugene Lambert, MD
11:50 – 12:50 PM Lunch Break
MODULE TOPIC 7: Polysubstance Use
12:50 – 1:10 PM Fundamentals of Polysubstance Use
Timothy E. Wilens, MD
1:10 – 1:30 PM Polysubstance Use Cases
Laura G. Kehoe, MD, MPH, FASAM
1:30 – 2:10 PM Panel Discussion
Moderator: Robert R. Althoff, MD, PhD
Panelists: Timothy E. Wilens, MD, Laura G. Kehoe, MD, MPH, FASAM
2:10 – 2:30 PM Coffee Break
MODULE TOPIC 8: COMORBIDITY
2:30 – 2:50 PM Mood Disorders
Vinod Rao, MD
2:50 – 3:10 PM Pain
Jessica Gray, MD
3:10 – 3:30 PM ADHD
Timothy Wilens, MD
3:30 – 4:10 PM Panel Discussion
Moderator: Timothy Wilens, MD
Panelists: Vinod Rao, MD, Robert R. Althoff, MD, PhD, Jessica Gray, MD
4:10 PM Adjourn
WEDNESDAY, FEBRUARY 22, 2023
8:00 – 8:10 AM Welcome & Introduction
David Rubin, MD
MODULE TOPIC 9: MARIJUANA & SYNTHETICS
8:10 – 8:30 AM Marijuana 101
Timothy E. Wilens, MD
8:30 – 8:50 AM Clinical Management
Robert R. Althoff, MD, PhD
8:50 – 9:10 AM Synthetics, Kratom & Designer Drugs
Timothy E. Wilens, MD
9:10 – 9:50 AM Panel Discussion
Moderator: David Rubin, MD
Panelists: Robert R. Althoff, MD, PhD, Timothy E. Wilens, MD
9:50 – 10:10 AM Coffee Break
MODULE TOPIC 10: STIMULANTS
10:10 – 10:30 AM Inpatient Methamphetamine
Timothy E. Wilens, MD
10:30 – 10:50 AM Outpatient Methamphetamine
Justin Alves, RN, MSN, ACRN, CARN, CNE
10:50 – 11:10 AM Cocaine, Rx Stimulants
Timothy E. Wilens, MD
11:10 – 11:50 AM Panel Discussion
Moderator: Timothy Willens, MD
Panelists: Justin Alves, RN, MSN, ACRN, CARN, CNE
11:50 AM Adjourn
Disney's Wilderness Lodge
901 Timberline Drive
Lake Buena Vista, FL 32830-8426 United States
+1 (407) 824-3000
The room blocks at both the Grand Floridian Resort & Spa, Wilderness Lodge, and Animal Kingdom Lodge have sold out.
For those who have yet to book a hotel room at the Grand Floridian Resort and Spa or Animal Kingdom Lodge, please note that the room blocks have sold out. Attendees are welcome to reach out to the resorts in case any additional rooms open up due to cancellations, however, there are many other local hotel options in the Lake Buena Vista area.
Disney's Animal Kingdom Lodge
2901 Osceola Pkwy
Lake Buena Vista, FL 32830 United States
+1 (407) 939-1936
The room blocks at both the Grand Floridian Resort & Spa, Wilderness Lodge, and Animal Kingdom Lodge have sold out.
Join us at Disney's Grand Floridian Resort & Spa for our annual Substance Use Disorder Conference
Please Note*** There is no transportation from the Wilderness Lodge and Animal Kingdom Lodge to the Grand Floridian. Please plan accordingly for travel to the conference.
Victorian elegance meets modern sophistication at this lavish Disney Resort hotel. Unwind outdoors, indulge in a luxurious massage and watch evening fireworks light up the sky over Cinderella Castle. Just one stop to Magic Kingdom park on the complimentary Resort Monorail, this timeless Victorian-style marvel evokes Palm Beach’s golden era.
We are offering our valued attendees a special discounted room rate.
The room blocks at both the Grand Floridian Resort & Spa, Wilderness Lodge, and Animal Kingdom Lodge have sold out.
We have arranged a special discounted rate for our valued Substance User Disorder 2023 attendees. Please note, discount hotel room reservations can only be honored for those that register for the course. Rooms booked without an accompanying MGH (Massachusetts General Hospital) course registration are subject to cancellation.
Robert R. Althoff, MD, PhD
Justin Alves, RN, MSN, ACRN, CARN, CNE
Jessica Gray, MD
Laura G. Kehoe, MD, MPH, FASAM
John F. Kelly, PhD
Eugene Lambert, MD
Vinod Rao, MD, PhD
David H. Rubin, MD
Timothy E. Wilens, MD
Available Credit
- 17.00 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.
McLean Hospital designates this Enduring activity for a maximum of 17.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 17.00 Nursing Contact Hours
Massachusetts General Laws, Chapter 13, sections 13, 14, 14A, 15 and 15D and Chapter 112, sections 74 through 81C authorize the Board of Registration in Nursing to regulate nursing practice and education.
This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 17.00 contact hours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet the requirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.
- 17.00 Social Workers
The Collaborative of NASW, Boston College, and Simmons College Schools of Social Work authorizes social work continuing education credits for courses, workshops, and educational programs that meet the criteria outlined in 258 CMR of the Massachusetts Board of Registration of Social Workers
This program has been approved for 17.00 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 91486
- 17.00 Participation
This course allows other providers to claim a Participation Certificate upon successful completion of this course.
Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credit™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credit™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.
- 17.00 Psychologists CE Credit
The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association to sponsor continuing education for psychologists. The Massachusetts General Hospital Department of Psychiatry maintains responsibility for this program and its content.
This offering meets the criteria for 17.00 Continuing Education (CE) credits per presentation for psychologists.
Price
Important: Buprenorphine (MAT) Waiver Training Registrants
You will need to create an account in the PCSS system ahead of the live training. If you do not set up an account and enroll in your training ahead of time, it will delay your ability to complete the online half and receive their certificate of completion. Please use this link to create an account https://education.sudtraining.org/Public/Registration.aspx Once you have created an account in the PCSS system, please use this link to enroll in the online half of this course: https://education.sudtraining.org/Users/InvitationCode.aspx You will submit this code: WAIVER-250359-11951
Once you have entered the invitation code, click “Get Started”, you will have access to the online half of the training. You may complete the online half before or after our live training. After the live training our staff will indicate your attendance. Once both halves of the training are complete you may return to the PCSS platform, complete their evaluation and claim your waiver training certificate.
Effective December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act):
- All DEA registrants should be aware of the following:
- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- The Act does not impact existing state laws or regulations that may be applicable.
While no longer required, the Act also introduced new training requirements for all prescribers who are not board certified in addiction medicine. These requirements will go into effect June 21, 2023, and the DEA and SAMHSA are actively working to provider further guidance.
As such, the MGH Psychiatry Academy welcomes all providers who plan to treat patients with opioid use disorder to make use of existent waiver trainings and other educational resources. Please continue to check https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement for further updates and guidance.